Template:Vasopressor table - Revision history

Danbot: Add MedicationDose SMW annotations for all vasopressors — dosing verified against SSC 2021

2026-03-20T15:50:57Z

Add MedicationDose SMW annotations for all vasopressors — dosing verified against SSC 2021

← Revisión anterior		Revisión del 15:50 20 mar 2026
Línea 25:		Línea 25:
	\|}		\|}
	{{Vasopressor critical care table}}		{{Vasopressor critical care table}}
			<div style="display:none">
			{{MedicationDose\|drug=Norepinephrine\|dose=2-5 mcg/min (0.01-0.03 mcg/kg/min), max 0.5-1 mcg/kg/min\|route=IV drip\|context=1st line vasopressor\|indication=Vasopressors\|population=Adult\|notes=1st line for septic shock (SSC 2021)}}
			{{MedicationDose\|drug=Epinephrine\|dose=1-10 mcg/min (0.01-0.1 mcg/kg/min), max 0.5 mcg/kg/min\|route=IV drip\|context=2nd/3rd line vasopressor\|indication=Vasopressors\|population=Adult\|notes=1st line for anaphylaxis and cardiac arrest}}
			{{MedicationDose\|drug=Vasopressin\|dose=0.03 U/min (fixed dose), max 0.04 U/min\|route=IV drip\|context=2nd line vasopressor\|indication=Vasopressors\|population=Adult\|notes=Add to NE rather than escalating NE (SSC 2021)}}
			{{MedicationDose\|drug=Dopamine\|dose=2-5 mcg/kg/min, max 20 mcg/kg/min\|route=IV drip\|context=Vasopressor\|indication=Vasopressors\|population=Adult\|notes=SSC 2021 suggests against as 1st line; more arrhythmogenic than NE}}
			{{MedicationDose\|drug=Dobutamine\|dose=2-5 mcg/kg/min, max 20 mcg/kg/min\|route=IV drip\|context=Inotrope\|indication=Vasopressors\|population=Adult\|notes=Inotrope, not a vasopressor; use with vasopressor if hypotensive}}
			{{MedicationDose\|drug=Phenylephrine\|dose=100-180 mcg/min, then 40-60 mcg/min\|route=IV drip\|context=Pure alpha vasopressor\|indication=Vasopressors\|population=Adult\|notes=Pure alpha-1 agonist; short duration 5-20 min}}
			{{MedicationDose\|drug=Milrinone\|dose=0.375-0.75 mcg/kg/min (loading often omitted)\|route=IV drip\|context=Inodilator\|indication=Vasopressors\|population=Adult\|notes=Inodilator; causes hypotension; useful in RV failure/pulmonary HTN}}
			{{MedicationDose\|drug=Methylene blue\|dose=1-2 mg/kg IV bolus over 15 min\|route=IV\|context=Salvage vasopressor\|indication=Vasopressors\|population=Adult\|notes=Salvage for refractory vasodilatory shock; contraindicated in G6PD deficiency}}
			{{MedicationDose\|drug=Angiotensin II\|dose=20 ng/kg/min, max 40-80 ng/kg/min\|route=IV drip\|context=Salvage vasopressor\|indication=Vasopressors\|population=Adult\|display=Angiotensin II (Giapreza)\|notes=Salvage for refractory vasodilatory shock (ATHOS-3 trial)}}
			</div>

Ostermayer at 12:02, 10 March 2026

2026-03-10T12:02:09Z

← Revisión anterior		Revisión del 12:02 10 mar 2026
Línea 1:		Línea 1:
	===[[Vasopressors]]===		===[[Vasopressors]]===
	{\| class="wikitable"f		''Vasopressors may be initiated peripherally while central access is being obtained — do not delay for central line placement (SSC 2021).''<ref name="SSC2021">Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143.</ref>

			{\| class="wikitable"
	\|-		\|-
	! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes		! Pressor !! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes
	\|-		\|-
	\| [[Dobutamine]] \|\| 3-5 mcg/kg/min \|\| ~~5-15~~ mcg/kg/min (~~as high as 200~~) <ref>~~https://www~~.~~ncbi~~.~~nlm~~.~~nih~~.~~gov/pubmed/8449087~~ </ref> \|\| Strong ß1 agonist +inotrope +chronotrope~~, Weak ß2~~ agonist +~~weak vasodilatation~~ ) \|\| ~~alpha~~ effect ~~minimal~~ \|\| HR ~~variable~~ effects.\|\| ~~indicated~~ in decompensated systolic ~~HF, Debut Research 1979<ref>Edmund H. Sonnenblick, M.D., William H. Frishman, M.D.,~~ and ~~Thierry H~~. ~~LeJemtel, M~~.D. ~~Dobutamine: A New Synthetic Cardioactive Sympathetic Amine</ref> Isoproterenol has most Β2 vasodilatory and Β1 HR effects~~		\| [[Dobutamine]] \|\| 2-5 mcg/kg/min \|\| 20 mcg/kg/min (up to 40 in refractory cases)<ref>Unverferth DV, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med. 1980;69(2):262-6.</ref> \|\| Strong β₁ agonist (+inotrope, +chronotrope); weak β₂ agonist (+vasodilation) \|\| Minimal α effect; '''may decrease''' BP due to β₂ vasodilation \|\| Variable HR effects; can cause tachycardia \|\| Indicated in decompensated systolic [[CHF]] and cardiogenic shock with adequate BP. Not a vasopressor — it is an '''inotrope'''. Must be used with a vasopressor if hypotensive.
	\|-		\|-
	\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20~~-50~~ mcg/kg/min \|\| β1 and ~~NorEpi~~ release \|\| α effects ~~if > 20mcg/kg/min~~ \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to ~~Norepi~~<ref name="soap2">De Backer ~~Daniel~~ et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>		\| [[Dopamine]] \|\| 2-5 mcg/kg/min \|\| 20 mcg/kg/min \|\| β₁ and endogenous norepinephrine release \|\| Mixed α and β effects at all doses; α effects predominate at higher doses \|\| '''Arrhythmogenic''' from β₁ effects \|\| More adverse events (especially arrhythmia) when used in shock compared to norepinephrine<ref name="soap2">De Backer D, et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM. 2010;363(9):779-789.</ref>. SSC 2021 suggests '''against''' dopamine as first-line except in select patients with bradycardia and low risk of tachyarrhythmia.
	\|-		\|-
	\| [[~~Epinepherine~~]] \|\|0.1-1 mcg/kg/min\|\| \|\| + ~~inotropy~~, + chronotropy \|\| \|\| \|\|		\| [[Epinephrine]] \|\| 1-10 mcg/min (0.01-0.1 mcg/kg/min) \|\| 0.5 mcg/kg/min \|\| +Inotropy, +chronotropy (β₁) \|\| Low dose: β₂ vasodilation may predominate; high dose: α₁ vasoconstriction predominates \|\| Significant — tachycardia, SVT, VT. Increases myocardial O₂ demand. \|\| '''2nd or 3rd line''' for septic shock (SSC 2021: add after norepinephrine ± vasopressin). '''1st line''' for [[anaphylaxis]] (0.3-0.5 mg IM) and [[cardiac arrest]]. May cause splanchnic vasoconstriction, lactic acidosis, and hyperglycemia.
	\|-		\|-
	\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (~~5mcg~~/kg/min) <ref> ~~https://www~~.~~ncbi~~.~~nlm~~.~~nih.gov/pubmed/15542956~~ </ref> \|\| ~~mild β1~~ direct effect \|\| β1 and ~~strong α1,2 effects~~ \|\| Less ~~arrhythmias~~ than ~~Dopamine~~<ref name="soap2"></~~ref~~> \|\| ~~First~~ line for ~~sepsis~~. Increases MAP ~~with~~ vasoconstriction~~, increases~~ coronary perfusion pressure~~, little β2 effects~~.		\| [[Norepinephrine]] \|\| 2-5 mcg/min (0.01-0.03 mcg/kg/min) \|\| 0.5-1 mcg/kg/min (some sources up to 3.3 mcg/kg/min)<ref>Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest. 1993;103(6):1826-31.</ref> \|\| Mild β₁ direct effect (+inotropy) \|\| Strong α₁ and α₂ vasoconstriction; β₁ effect \|\| Less arrhythmogenic than dopamine<ref name="soap2"/> \|\| '''1st line for septic shock''' (SSC 2021)<ref name="SSC2021"/>. Increases MAP primarily via vasoconstriction. Increases coronary perfusion pressure. Minimal β₂ effect.
	\|-		\|-
	\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| ~~Direct~~ influx ~~of Ca<sup>2~~+~~</sup> channels~~\|\| ~~Smooth muscle~~ vasodilator \|\| \|\| ~~PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma~~. ~~No venodilatory activity~~		\| [[Milrinone]] \|\| 50 mcg/kg IV over 10 min (loading dose often '''omitted''' in acute illness due to hypotension risk) \|\| 0.375-0.75 mcg/kg/min \|\| PDE-3 inhibitor → ↑intracellular cAMP → ↑Ca²⁺ influx → +inotropy \|\| Arteriolar '''and''' venous vasodilator (reduces preload AND afterload) \|\| Less arrhythmogenic than dobutamine \|\| '''Inodilator''' — useful in decompensated HF with elevated afterload, RV failure, or pulmonary hypertension. '''Causes hypotension''' — not a vasopressor; use with a vasopressor if MAP is low. Renally cleared — dose-reduce in CKD.
	\|-		\|-
	\| [[Phenylephrine]] \|\| 100-180 mcg/min then 40-60 mcg/min \|\| 0.4-9 mcg/kg/min \|\| \|\| ~~Alpha~~ agonist \|\| \|\| ~~Long half life~~		\| [[Phenylephrine]] \|\| 100-180 mcg/min, then 40-60 mcg/min \|\| 0.4-9.1 mcg/kg/min \|\| No direct cardiac effect \|\| '''Pure α₁ agonist''' → vasoconstriction \|\| May cause reflex bradycardia \|\| '''Short''' duration of action (5-20 min IV). Use in septic shock '''only if:''' NE causes arrhythmias, cardiac output is high with persistent hypotension, or as salvage when NE + vasopressin have failed.<ref name="SSC2021"/>
	\|-		\|-
	\| [[Vasopressin]] \|\| ~~Fixed Dose~~ \|\| ~~0.01 to~~ 0.04 U/min \|\| ~~unknown~~ \|\| ~~increases via ADH peptide~~ \|\| \|\| ~~should~~ not be titrated ~~due to ischemic effects~~		\| [[Vasopressin]] \|\| 0.03 U/min (fixed dose) \|\| 0.04 U/min \|\| No direct inotropic or chronotropic effect; possible reflex bradycardia \|\| V₁ receptor agonist → vascular smooth muscle constriction \|\| Minimal \|\| '''2nd line''' in septic shock — add to NE rather than escalating NE (SSC 2021 suggests adding before epinephrine)<ref name="SSC2021"/>. '''Fixed dose''' — generally not titrated. May reduce the risk of atrial fibrillation vs. catecholamine-only regimens.<ref>McIntyre WF, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock. JAMA. 2018;319(18):1889.</ref> Avoid dose >0.04 U/min → risk of cardiac and mesenteric ischemia.
	\|-		\|-
	\| [[Methylene blue]]<ref>Pasin L et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013 ~~Mar~~;15(1):42-8.</ref>\|\| IV bolus 2 mg/kg over 15 min \|\| 1-2 mg/kg/hour \|\| Possible increased inotropy, cardiac ~~use of~~ ATP \|\| Inhibits NO mediated peripheral vasodilation \|\| \|\| ~~Don~~'~~t use~~ in [[G6PD deficiency]], [[ARDS]], [[pulmonary hypertension]]		\| [[Methylene blue]]<ref>Pasin L, et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013;15(1):42-8.</ref> \|\| IV bolus 1-2 mg/kg over 15 min \|\| 1-2 mg/kg/hour (limited data on max duration) \|\| Possible increased inotropy; improves cardiac ATP utilization \|\| Inhibits NO-mediated peripheral vasodilation → increases SVR \|\| Minimal reported \|\| '''Salvage therapy''' for refractory vasodilatory shock unresponsive to catecholamines. '''Contraindicated''' in [[G6PD deficiency]] (hemolytic anemia), [[ARDS]], severe [[pulmonary hypertension]]. Interferes with [[pulse oximetry]] readings (falsely low SpO₂). Avoid with serotonergic drugs (risk of [[serotonin syndrome]]).
			\|-
			\| [[Angiotensin II]] (Giapreza) \|\| 20 ng/kg/min \|\| 40-80 ng/kg/min (max 200 ng/kg/min per label) \|\| No direct cardiac effect \|\| AT₁ receptor agonist → potent arteriolar vasoconstriction; also stimulates aldosterone secretion \|\| Minimal \|\| '''Salvage therapy''' for refractory vasodilatory shock (ATHOS-3 trial)<ref>Khanna A, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017;377(5):419-430.</ref>. May be particularly useful in patients on ACEi/ARB or with high renin states. Monitor for thrombosis (increased risk reported).
	\|}		\|}

	{{Vasopressor critical care table}}		{{Vasopressor critical care table}}

Rossdonaldson1: /* Vasopressors */

2022-12-07T22:48:13Z

Vasopressors

← Revisión anterior		Revisión del 22:48 7 dic 2022
Línea 1:		Línea 1:
	===[[Vasopressors]]===		===[[Vasopressors]]===
	{\| class="wikitable"		{\| class="wikitable"f
	\|-		\|-
	! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes		! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes
	\|-		\|-
	\| [[Dobutamine]] \|\| 3-5 mcg/kg/min \|\| 5-15 mcg/kg/min (as high as 200) <ref>https://www.ncbi.nlm.nih.gov/pubmed/8449087 </ref> \|\| Strong ß1 agonist +inotrope +chronotrope, Weak ß2 agonist +weak vasodilatation ) \|\| alpha effect minimal \|\| HR variable effects ~~<ref> </ref>~~. ~~Also Increase SA and AV node fx~~ \|\| indicated in decompensated systolic HF, Debut Research 1979<ref>Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine</ref> Isoproterenol has most Β2 vasodilatory and Β1 HR effects		\| [[Dobutamine]] \|\| 3-5 mcg/kg/min \|\| 5-15 mcg/kg/min (as high as 200) <ref>https://www.ncbi.nlm.nih.gov/pubmed/8449087 </ref> \|\| Strong ß1 agonist +inotrope +chronotrope, Weak ß2 agonist +weak vasodilatation ) \|\| alpha effect minimal \|\| HR variable effects.\|\| indicated in decompensated systolic HF, Debut Research 1979<ref>Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine</ref> Isoproterenol has most Β2 vasodilatory and Β1 HR effects
	\|-		\|-
	\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>		\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>

Cmolson: /* Vasopressors */

2020-12-21T17:50:36Z

Vasopressors

← Revisión anterior		Revisión del 17:50 21 dic 2020
Línea 16:		Línea 16:
	\| [[Phenylephrine]] \|\| 100-180 mcg/min then 40-60 mcg/min \|\| 0.4-9 mcg/kg/min \|\| \|\| Alpha agonist \|\| \|\| Long half life		\| [[Phenylephrine]] \|\| 100-180 mcg/min then 40-60 mcg/min \|\| 0.4-9 mcg/kg/min \|\| \|\| Alpha agonist \|\| \|\| Long half life
	\|-		\|-
	\| [[Vasopressin]] \|\| Fixed Dose \|\| 0.4 U/min \|\| unknown \|\| increases via ADH peptide \|\| \|\| should not be titrated due to ischemic effects		\| [[Vasopressin]] \|\| Fixed Dose \|\| 0.01 to 0.04 U/min \|\| unknown \|\| increases via ADH peptide \|\| \|\| should not be titrated due to ischemic effects
	\|-		\|-
	\| [[Methylene blue]]<ref>Pasin L et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013 Mar;15(1):42-8.</ref>\|\| IV bolus 2 mg/kg over 15 min \|\| 1-2 mg/kg/hour \|\| Possible increased inotropy, cardiac use of ATP \|\| Inhibits NO mediated peripheral vasodilation \|\| \|\| Don't use in [[G6PD deficiency]], [[ARDS]], [[pulmonary hypertension]]		\| [[Methylene blue]]<ref>Pasin L et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013 Mar;15(1):42-8.</ref>\|\| IV bolus 2 mg/kg over 15 min \|\| 1-2 mg/kg/hour \|\| Possible increased inotropy, cardiac use of ATP \|\| Inhibits NO mediated peripheral vasodilation \|\| \|\| Don't use in [[G6PD deficiency]], [[ARDS]], [[pulmonary hypertension]]

Shihabali: /* Vasopressors */

2019-11-27T21:16:12Z

Vasopressors

← Revisión anterior		Revisión del 21:16 27 nov 2019
Línea 10:		Línea 10:
	\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| + inotropy, + chronotropy \|\| \|\| \|\|		\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| + inotropy, + chronotropy \|\| \|\| \|\|
	\|-		\|-
	\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (5mcg/kg/min) <ref> https://www.ncbi.nlm.nih.gov/pubmed/15542956 </ref> \|\| mild β1 direct effect \|\| β1 and strong α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP with vasoconstriction, increases coronary perfusion pressure, little β2 effects.		\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (5mcg/kg/min) <ref> https://www.ncbi.nlm.nih.gov/pubmed/15542956 </ref> \|\| mild β1 direct effect \|\| β1 and strong α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| First line for sepsis. Increases MAP with vasoconstriction, increases coronary perfusion pressure, little β2 effects.
	\|-		\|-
	\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity		\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity

Bristolschmitz: /* Vasopressors */

2018-08-01T15:07:35Z

Vasopressors

← Revisión anterior		Revisión del 15:07 1 ago 2018
Línea 10:		Línea 10:
	\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| + inotropy, + chronotropy \|\| \|\| \|\|		\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| + inotropy, + chronotropy \|\| \|\| \|\|
	\|-		\|-
	\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (5mcg/kg/min) <ref> https://www.ncbi.nlm.nih.gov/pubmed/15542956 </ref> \|\| mild β1 direct effect \|\| β1 and strong α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP with vasoconstriction, ~~increasescoronary~~ perfusion pressure, little β2 effects.		\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (5mcg/kg/min) <ref> https://www.ncbi.nlm.nih.gov/pubmed/15542956 </ref> \|\| mild β1 direct effect \|\| β1 and strong α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP with vasoconstriction, increases coronary perfusion pressure, little β2 effects.
	\|-		\|-
	\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity		\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity

Kramarsh: /* Vasopressors */

2018-03-24T04:29:11Z

Vasopressors

← Revisión anterior		Revisión del 04:29 24 mar 2018
Línea 8:		Línea 8:
	\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>		\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>
	\|-		\|-
	\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| \|\| \|\| \|\|		\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| + inotropy, + chronotropy \|\| \|\| \|\|
	\|-		\|-
	\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (5mcg/kg/min) <ref> https://www.ncbi.nlm.nih.gov/pubmed/15542956 </ref> \|\| mild β1 direct effect \|\| β1 and strong α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP with vasoconstriction, increasescoronary perfusion pressure, little β2 effects.		\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (5mcg/kg/min) <ref> https://www.ncbi.nlm.nih.gov/pubmed/15542956 </ref> \|\| mild β1 direct effect \|\| β1 and strong α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP with vasoconstriction, increasescoronary perfusion pressure, little β2 effects.

Panosiaa: /* Vasopressors */

2017-07-13T22:37:02Z

Vasopressors

← Revisión anterior		Revisión del 22:37 13 jul 2017
Línea 4:		Línea 4:
	! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes		! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes
	\|-		\|-
	\| [[Dobutamine]] \|\| 2.5 mcg/kg/min \|\| 10-40 mcg/kg/min \|\| ~~mainly~~ inotrope ~~(ß1~~) \|\| alpha effect minimal \|\| ~~Some~~ HR~~(ß1) increase~~. Also Increase SA and AV node fx \|\| Debut Research 1979<ref>Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine</ref> Isoproterenol has most Β2 vasodilatory and Β1 HR effects		\| [[Dobutamine]] \|\| 3-5 mcg/kg/min \|\| 5-15 mcg/kg/min (as high as 200) <ref>https://www.ncbi.nlm.nih.gov/pubmed/8449087 </ref> \|\| Strong ß1 agonist +inotrope +chronotrope, Weak ß2 agonist +weak vasodilatation ) \|\| alpha effect minimal \|\| HR variable effects <ref> </ref>. Also Increase SA and AV node fx \|\| indicated in decompensated systolic HF, Debut Research 1979<ref>Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine</ref> Isoproterenol has most Β2 vasodilatory and Β1 HR effects
	\|-		\|-
	\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>		\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>
	\|-		\|-
	\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| \|\| \|\| \|\|		\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| \|\| \|\| \|\|
	\|-		\|-
	\| [[Norepinephrine]] \|\| ~~8-12~~ mcg/min \|\| 30 mcg/min \|\| β1 direct effect \|\| β1 and α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP, ~~coronary~~ perfusion pressure, little β2 effects.		\| [[Norepinephrine]] \|\| 0.2 mcg/kg/min \|\| 0.2-1.3 mcg/kg/min (5mcg/kg/min) <ref> https://www.ncbi.nlm.nih.gov/pubmed/15542956 </ref> \|\| mild β1 direct effect \|\| β1 and strong α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP with vasoconstriction, increasescoronary perfusion pressure, little β2 effects.
	\|-		\|-
	\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity		\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity

Kxl328 at 23:46, 26 February 2017

2017-02-26T23:46:58Z

← Revisión anterior		Revisión del 23:46 26 feb 2017
Línea 4:		Línea 4:
	! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes		! Pressor!! Initial Dose !! Max Dose !! Cardiac Effect !! BP Effect !! [[Arrhythmias]] !! Special Notes
	\|-		\|-
	\| [[Dobutamine]] \|\| 2.~~5mcg~~/kg/min \|\| 10-40 mcg/kg/min \|\| mainly inotrope (ß1) \|\| alpha effect minimal \|\| Some HR(ß1) increase. Also Increase SA and AV node fx \|\| Debut Research 1979<ref>Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine</ref> Isoproterenol has most Β2 vasodilatory and Β1 HR effects		\| [[Dobutamine]] \|\| 2.5 mcg/kg/min \|\| 10-40 mcg/kg/min \|\| mainly inotrope (ß1) \|\| alpha effect minimal \|\| Some HR(ß1) increase. Also Increase SA and AV node fx \|\| Debut Research 1979<ref>Edmund H. Sonnenblick, M.D., William H. Frishman, M.D., and Thierry H. LeJemtel, M.D. Dobutamine: A New Synthetic Cardioactive Sympathetic Amine</ref> Isoproterenol has most Β2 vasodilatory and Β1 HR effects
	\|-		\|-
	\| [[Dopamine]] \|\| ~~2mcg~~/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>		\| [[Dopamine]] \|\| 2 mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>
	\|-		\|-
	\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| \|\| \|\| \|\|		\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| \|\| \|\| \|\|
	\|-		\|-
	\| [[Norepinephrine]] \|\| 8-~~12mcg~~/min \|\| 30 mcg/min \|\| β1 direct effect \|\| β1 and α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP, coronary perfusion pressure, little β2 effects.		\| [[Norepinephrine]] \|\| 8-12 mcg/min \|\| 30 mcg/min \|\| β1 direct effect \|\| β1 and α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP, coronary perfusion pressure, little β2 effects.
	\|-		\|-
	\|[[Milrinone]] \|\| ~~50mcg~~/kg x 10 min \|\| 0.375-~~75mcg~~/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity		\|[[Milrinone]] \|\| 50 mcg/kg x 10 min \|\| 0.375-75 mcg/kg/min \|\| Direct influx of Ca<sup>2+</sup> channels\|\| Smooth muscle vasodilator \|\| \|\| PDE Inhibitor which increases Ca<sup>2+</sup> uptake by sarcolemma. No venodilatory activity
	\|-		\|-
	\| [[Phenylephrine]] \|\| 100-~~180mcg~~/min then 40-~~60mcg~~/min \|\| 0.4-9 mcg/kg/min \|\| \|\| Alpha agonist \|\| \|\| Long half life		\| [[Phenylephrine]] \|\| 100-180 mcg/min then 40-60 mcg/min \|\| 0.4-9 mcg/kg/min \|\| \|\| Alpha agonist \|\| \|\| Long half life
	\|-		\|-
	\| [[Vasopressin]] \|\| Fixed Dose \|\| 0.4 U/min \|\| unknown \|\| increases via ADH peptide \|\| \|\| should not be titrated due to ischemic effects		\| [[Vasopressin]] \|\| Fixed Dose \|\| 0.4 U/min \|\| unknown \|\| increases via ADH peptide \|\| \|\| should not be titrated due to ischemic effects
			\|-
			\| [[Methylene blue]]<ref>Pasin L et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013 Mar;15(1):42-8.</ref>\|\| IV bolus 2 mg/kg over 15 min \|\| 1-2 mg/kg/hour \|\| Possible increased inotropy, cardiac use of ATP \|\| Inhibits NO mediated peripheral vasodilation \|\| \|\| Don't use in [[G6PD deficiency]], [[ARDS]], [[pulmonary hypertension]]
	\|}		\|}

	{{Vasopressor critical care table}}		{{Vasopressor critical care table}}

Rossdonaldson1: /* Vasopressors */

2015-05-04T14:41:36Z

Vasopressors

← Revisión anterior		Revisión del 14:41 4 may 2015
Línea 7:		Línea 7:
	\|-		\|-
	\| [[Dopamine]] \|\| 2mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>		\| [[Dopamine]] \|\| 2mcg/kg/min \|\| 20-50 mcg/kg/min \|\| β1 and NorEpi release \|\| α effects if > 20mcg/kg/min \|\| Arrhythmogenic from β1 effects \|\| More adverse events when used in shock compared to Norepi<ref name="soap2">De Backer Daniel et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 363(9). 779-789</ref>
			\|-
			\| [[Epinepherine]] \|\|0.1-1 mcg/kg/min\|\| \|\| \|\| \|\| \|\|
	\|-		\|-
	\| [[Norepinephrine]] \|\| 8-12mcg/min \|\| 30 mcg/min \|\| β1 direct effect \|\| β1 and α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP, coronary perfusion pressure, little β2 effects.		\| [[Norepinephrine]] \|\| 8-12mcg/min \|\| 30 mcg/min \|\| β1 direct effect \|\| β1 and α1,2 effects \|\| Less arrhythmias than Dopamine<ref name="soap2"></ref> \|\| Increases MAP, coronary perfusion pressure, little β2 effects.